氨磺必利治疗慢性精神分裂症疗效分析

Analysis of Curative Effect of Amisulpride in the Treatment of Chronic Schizophrenia

目的:探讨氨磺必利治疗慢性精神分裂症的疗效及安全性。方法:选择2015年3月-2016年2月在我科治疗的确诊为慢性精神分裂症患者98例作为研究对象,按随机数字表法分为对照组和观察组,各49例。对照组采用利培酮(1~6 mg,qd)治疗;观察组采用氨磺必利(200~600 mg,qd)治疗。比较两组治疗前、后阳性和阴性症状量表(PANSS)各项评分、疗效以及不良反应。结果 :治疗前两组PANSS各项评分比较无统计学差异(P>0.05);治疗后两组阳性症状及一般病理性症状比较无统计学差异(P>0.05),治疗后两组阴性症状及PANSS总分比较,观察组优于对照组(P<0.05)。两组有效率比较,观察组优于对照组(P<0.05)。观察组不良反应发生率明显低于对照组(P<0.05)。结论 :应用氨磺必利治疗慢性精神分裂症临床疗效好,安全性高,值得临床推广应用。

Objective:To investigate the efficacy and safety of amisulpride in the treatment of chronic schizophrenia. Methods:98 patients with chronic schizophrenia from March 2015 to February 2016 were divided into the control group and the observation group according to random number table, 49 cases in each group. The control group was treated with risperidone(1~6 mg, qd); The observation group was treated with amisulpride(200~600 mg, qd). The positive and negative symptom scale(PANSS) scores, curative effects and adverse reactions were compared between the two groups before and after treatment. Results:There was no significant difference in the PANSS scores between the two groups before treatment(P>0.05). After treatment, there was no significant difference in positive symptoms and general pathological symptoms between the two groups(P>0.05). After treatment, negative symptoms and the PANSS total scores of the observation group were better than those of control group(P<0.05). The effective rate of the observation group was better than that of the control group(P<0.05). The incidence of adverse reactions of the observation group was significantly lower than that of the control group(P<0.05). Conclusion:The application of amisulpride in treatment of chronic schizophrenia has good clinical effect, high safety, it is worthy of clinical application.